Literature DB >> 26033280

Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia.

Yoshihiro Inamoto1, Mary E D Flowers2, Tao Wang3, Alvaro Urbano-Ispizua4, Michael T Hemmer5, Corey S Cutler6, Daniel R Couriel7, Amin M Alousi8, Joseph H Antin6, Robert Peter Gale9, Vikas Gupta10, Betty K Hamilton11, Mohamed A Kharfan-Dabaja12, David I Marks13, Olle T H Ringdén14, Gérard Socié15, Melhem M Solh16, Görgün Akpek17, Mitchell S Cairo18, Nelson J Chao19, Robert J Hayashi20, Taiga Nishihori12, Ran Reshef21, Ayman Saad22, Ami Shah23, Takanori Teshima24, Martin S Tallman25, Baldeep Wirk26, Stephen R Spellman27, Mukta Arora28, Paul J Martin2.   

Abstract

Combinations of cyclosporine (CSP) with methotrexate (MTX) have been widely used for immunosuppression after allogeneic transplantation for acquired aplastic anemia. We compared outcomes with tacrolimus (TAC)+MTX versus CSP+MTX after transplantation from HLA-identical siblings (SIB) or unrelated donors (URD) in a retrospective cohort of 949 patients with severe aplastic anemia. Study endpoints included hematopoietic recovery, graft failure, acute graft-versus-host disease (GVHD), chronic GVHD, and mortality. TAC+MTX was used more frequently in older patients and, in recent years, in both SIB and URD groups. In multivariate analysis, TAC+MTX was associated with a lower risk of mortality in URD recipients and with slightly earlier absolute neutrophil count recovery in SIB recipients. Other outcomes did not differ statistically between the 2 regimens. No firm conclusions were reached regarding the relative merits of TAC+MTX versus CSP+MTX after hematopoietic cell transplantation for acquired aplastic anemia. Prospective studies would be needed to determine whether the use of TAC+MTX is associated with lower risk of mortality in URD recipients with acquired aplastic anemia.
Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aplastic anemia; Cyclosporine; Graft-versus-host disease; Hematopoietic cell transplantation; Immunosuppression; Tacrolimus

Mesh：

Substances：

Year:  2015        PMID： 26033280      PMCID： PMC4568149          DOI： 10.1016/j.bbmt.2015.05.023

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


  25 in total

1.  Estimation of multivariate frailty models using penalized partial likelihood.

Authors:  S Ripatti; J Palmgren
Journal:  Biometrics       Date:  2000-12       Impact factor: 2.571

2.  A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells.

Authors:  Yoshihiro Inamoto; Mary E D Flowers; Frederick R Appelbaum; Paul A Carpenter; H Joachim Deeg; Terry Furlong; Hans-Peter Kiem; Marco Mielcarek; Richard A Nash; Rainer F Storb; Robert P Witherspoon; Barry E Storer; Paul J Martin
Journal:  Biol Blood Marrow Transplant       Date:  2011-03-21       Impact factor: 5.742

3.  Comparison of outcomes after transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia.

Authors:  Roland Chu; Ruta Brazauskas; Fangyu Kan; Asad Bashey; Christopher Bredeson; Bruce Camitta; Kuang-Yueh Chiang; Haydar Frangoul; Robert Peter Gale; Adrian Gee; Biju George; Frederick D Goldman; Thomas G Gross; Vikas Gupta; Gregory A Hale; Luis Isola; Alvaro Urbano Ispizua; Hillard Lazarus; Judith Marsh; James Russell; Mitchell Sabloff; Edmund K Waller; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-27       Impact factor: 5.742

4.  Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups.

Authors:  Andrea Bacigalupo; Gérard Socié; Hubert Schrezenmeier; Andre Tichelli; Anna Locasciulli; Monika Fuehrer; Antonio M Risitano; Carlo Dufour; Jakob R Passweg; Rosi Oneto; Mahmoud Aljurf; Catherine Flynn; Valerie Mialou; Rose Marie Hamladji; Judith C W Marsh
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

5.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation.

Authors:  Madan Jagasia; Mukta Arora; Mary E D Flowers; Nelson J Chao; Philip L McCarthy; Corey S Cutler; Alvaro Urbano-Ispizua; Steven Z Pavletic; Michael D Haagenson; Mei-Jie Zhang; Joseph H Antin; Brian J Bolwell; Christopher Bredeson; Jean-Yves Cahn; Mitchell Cairo; Robert Peter Gale; Vikas Gupta; Stephanie J Lee; Mark Litzow; Daniel J Weisdorf; Mary M Horowitz; Theresa Hahn
Journal:  Blood       Date:  2011-10-18       Impact factor: 22.113

6.  Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial.

Authors:  F Locatelli; M Zecca; R Rondelli; F Bonetti; G Dini; A Prete; C Messina; C Uderzo; M Ripaldi; F Porta; G Giorgiani; E Giraldi; A Pession
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

7.  Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.

Authors:  R A Nash; J H Antin; C Karanes; J W Fay; B R Avalos; A M Yeager; D Przepiorka; S Davies; F B Petersen; P Bartels; D Buell; W Fitzsimmons; C Anasetti; R Storb; V Ratanatharathorn
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

8.  Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation.

Authors:  A Hiraoka; Y Ohashi; S Okamoto; Y Moriyama; T Nagao; Y Kodera; A Kanamaru; H Dohy; T Masaoka
Journal:  Bone Marrow Transplant       Date:  2001-07       Impact factor: 5.483

9.  Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party.

Authors:  Andrea Bacigalupo; Gerard Socie'; Edoardo Lanino; Arcangelo Prete; Franco Locatelli; Anna Locasciulli; Simone Cesaro; Avichai Shimoni; Judith Marsh; Mats Brune; Maria Teresa Van Lint; Rosi Oneto; Jacob Passweg
Journal:  Haematologica       Date:  2010-05-21       Impact factor: 9.941

10.  Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program.

Authors:  Seiji Kojima; Takaharu Matsuyama; Shunichi Kato; Hisato Kigasawa; Ryoji Kobayashi; Atsushi Kikuta; Hisashi Sakamaki; Koichiro Ikuta; Masahiro Tsuchida; Yasutaka Hoshi; Yasuo Morishima; Yoshihisa Kodera
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113
View more
  7 in total

Review 1.  Hematopoietic stem cell transplantation for acquired aplastic anemia.

Authors:  George E Georges; Rainer Storb
Journal:  Curr Opin Hematol       Date:  2016-11       Impact factor: 3.284

2.  Long-term outcome and chimerism in patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation: a retrospective nationwide survey.

Authors:  Akihiro Iguchi; Yuko Cho; Hiromasa Yabe; Shunichi Kato; Koji Kato; Junichi Hara; Katsuyoshi Koh; Junko Takita; Takashi Ishihara; Masami Inoue; Kohsuke Imai; Hideki Nakayama; Yoshiko Hashii; Akira Morimoto; Yoshiko Atsuta; Tomohiro Morio
Journal:  Int J Hematol       Date:  2019-06-11       Impact factor: 2.490

3.  Outcomes of matched sibling donor bone marrow transplantation in children using single-agent calcineurin inhibitors as prophylaxis for graft versus host disease.

Authors:  Caitlin W Elgarten; Danielle E Arnold; Nancy J Bunin; Alix E Seif
Journal:  Pediatr Blood Cancer       Date:  2017-07-27       Impact factor: 3.167

4.  Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.

Authors:  Yoshihiro Inamoto; Fumihiko Kimura; Junya Kanda; Junichi Sugita; Kazuhiro Ikegame; Hideki Nakasone; Yasuhito Nannya; Naoyuki Uchida; Takahiro Fukuda; Kosuke Yoshioka; Yukiyasu Ozawa; Ichiro Kawano; Yoshiko Atsuta; Koji Kato; Tatsuo Ichinohe; Masami Inoue; Takanori Teshima
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

5.  Effective Tacrolimus Treatment for Patients with Non-Severe Aplastic Anemia That is Refractory/Intolerant to Cyclosporine A: A Retrospective Study.

Authors:  Yali Du; Yuzhou Huang; Wenzhe Zhou; Xinjian Liu; Fangfei Chen; Chen Yang; Miao Chen; Jing Ruan; Bing Han
Journal:  Drug Des Devel Ther       Date:  2020-12-30       Impact factor: 4.162

6.  Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series.

Authors:  Anastasia Martynova; Victor Chiu; Melissa Mert; David Hermel; Ilene Ceil Weitz
Journal:  Ann Hematol       Date:  2021-01-09       Impact factor: 3.673

7.  Impact of Low-Dose rATG Prior to Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: Reduced Risk of Chronic Graft-versus-Host Disease and Improved Survival Outcomes.

Authors:  Zheng-Yang Song; Han-Yun Ren; Yu-Jun Dong; Yuan Li; Yue Yin; Yu-Hua Sun; Qian Wang; Wei-Lin Xu; Wei Liu; Jin-Ping Ou; Ze-Yin Liang
Journal:  Cancer Manag Res       Date:  2020-11-30       Impact factor: 3.989
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.